Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer-Reference-Cited by-同舟云学术

Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer

Published:2021-09 Issue:3 Volume:162 Page:720-727
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Werner Bonnita,Yuwono Nicole,Duggan Jennifer,Liu Dongli,David Catherine,Srirangan Sivatharsny,Provan Pamela,DeFazio Anna,Arora Vivek,Farrell Rhonda,Lee Yeh Chen,Warton Kristina,Ford Caroline

Funder

University of Sydney

AstraZeneca

Cancer Council New South Wales

Cancer Institute NSW

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference22 articles.

1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;Ferlay;Int. J. Cancer,2019

2. Ovarian cancer statistics, 2018;Torre;CA Cancer J. Clin.,2018

3. The untapped potential of ascites in ovarian cancer research and treatment;Ford;Br. J. Cancer,2020

4. Malignant peritoneal effusion acting as a tumor environment in ovarian cancer progression: impact and significance;Piche;World J. Clin. Oncol.,2018

5. Ovarian cancer development and metastasis;Lengyel;Am. J. Pathol.,2010

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cell‐free DNA from ascites identifies clinically relevant variants and tumour evolution in patients with advanced ovarian cancer;Molecular Oncology;2024-08-08

2. A Fast, Affordable, and Minimally Invasive Diagnostic Test for Cancer of Unknown Primary Using DNA Methylation Profiling;Laboratory Investigation;2024-08

3. Clinical relevance of circulating tumor DNA in ovarian cancer: current issues and future opportunities;Exploration of Targeted Anti-tumor Therapy;2024-06-19

4. Cell-free DNA in plasma and ascites as a biomarker of bevacizumab response- a translational research sub-study of the REZOLVE (ANZGOG-1101) clinical trial;Translational Oncology;2024-05

5. Germline and somatic testing for ovarian Cancer: An SGO clinical practice statement;Gynecologic Oncology;2024-02